公开(公告)号：US20180369404A1

公开(公告)日：2018-12-27

申请号：US15991745

申请日：2018-05-29

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan ORONSKY ,  Tony R. REID

IPC: A61K47/68 ,  C12N15/85 ,  A61P35/00 ,  A61K47/69 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N7/04

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US20210139560A1

公开(公告)日：2021-05-13

申请号：US17150993

申请日：2021-01-15

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Tony R. REID ,  Bryan T. ORONSKY

IPC: C07K14/71 ,  C12N7/00 ,  A61P35/00 ,  C07K16/00 ,  C12N15/86

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20200345690A1

公开(公告)日：2020-11-05

申请号：US16960444

申请日：2019-01-08

Applicant: EpicentRx Inc.

Inventor： Bryan T. ORONSKY ,  Amold ORONSKY ,  Tony R. REID

IPC: A61K31/397

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

公开(公告)号：US20250074967A1

公开(公告)日：2025-03-06

申请号：US18772025

申请日：2024-07-12

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Tony R. REID ,  Bryan T. ORONSKY

IPC: C07K14/71 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20210015878A1

公开(公告)日：2021-01-21

申请号：US17042822

申请日：2019-03-28

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan T. ORONSKY ,  Tony R. REID

IPC: A61K35/761 ,  A61K38/16 ,  C12N15/10 ,  C12N15/861

Abstract: The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.

公开(公告)号：US20240382451A1

公开(公告)日：2024-11-21

申请号：US18570439

申请日：2022-06-16

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Scott CAROEN ,  Tony R. REID

IPC: A61K31/397 ,  A61K45/06 ,  A61P1/00 ,  A61P25/16 ,  A61P25/28 ,  A61P39/00

Abstract: Provided herein are methods of treating and preventing a disorder selected from the group consisting of an autoimmune disorder, inflammatory disorder, immune disorder, bone and joint disorder, neurodegenerative disorder, and neuromuscular disorder in a. subject in need thereof. The method includes administering an effective amount of an organonitro or sulfoxyalkyl organonitro compound to the subject, which may include using a dosing regimen that comprises administering loading and maintenance doses.

公开(公告)号：US20240293360A1

公开(公告)日：2024-09-05

申请号：US18568625

申请日：2022-06-09

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Tony R. REID ,  Christpoher LARSON ,  James KANTER

IPC: A61K31/397 ,  A61K9/14 ,  A61K35/14 ,  A61K47/10 ,  A61P35/00 ,  C07D205/04

CPC classification number: A61K31/397 ,  A61K9/145 ,  A61K35/14 ,  A61K47/10 ,  A61P35/00 ,  C07D205/04

Abstract: The present invention relates to a composition comprising solid crystalline, non-impact or non-detonation sensitive particles comprising 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), methods of preparing the crystalline form, and its use.

公开(公告)号：US20240148692A1

公开(公告)日：2024-05-09

申请号：US18211792

申请日：2023-06-20

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Tony R. REID ,  Arnold ORONSKY

IPC: A61K31/397

CPC classification number: A61K31/397 ,  A61K9/0014

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OOI and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OOI to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

公开(公告)号：US20250161548A1

公开(公告)日：2025-05-22

申请号：US18748892

申请日：2024-06-20

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Scott CAROEN ,  Tony R. REID ,  Jeannie WILLIAMS

IPC: A61M1/34 ,  A61M1/36 ,  A61M1/38

Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

公开(公告)号：US20240294883A1

公开(公告)日：2024-09-05

申请号：US18649467

申请日：2024-04-29

Applicant: EpicentRx, Inc.

Inventor： Tony R. REID ,  Bryan T. ORONSKY ,  Christopher LARSON

IPC: C12N7/00

CPC classification number: C12N7/00 ,  C12N2710/10321 ,  C12N2710/10322 ,  C12N2710/10332 ,  C12N2710/10352

Abstract: The present disclosure relates to compositions and methods for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.